Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Baxter
Johnson and Johnson
UBS
Cerilliant
McKesson
Cipla
Covington
QuintilesIMS

Generated: May 25, 2018

DrugPatentWatch Database Preview

OPTIVAR Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Optivar patents expire, and when can generic versions of Optivar launch?

Optivar is a drug marketed by Mylan Speciality Lp and is included in one NDA.

The generic ingredient in OPTIVAR is azelastine hydrochloride. There are twelve drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the azelastine hydrochloride profile page.
Drug patent expirations by year for OPTIVAR
Synonyms for OPTIVAR
1(2H)-Phthalazinone, 4-((4-chlorophenyl)methyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-, monohydrochloride
1(2H)-Phthalazinone, 4-((4-chlorophenyl)methyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-,monohydrochloride
1(2H)-Phthalazinone,4-[(4-chlorophenyl)methyl]-2-(hexahydro-1-methyl-1H-azepin-4-yl)-,hydrochloride (1:?)
307A930
37932-96-0
4-((4-Chlorophenyl)methyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)phthalazin-1(2H)-one hydrochloride
4-(4-Chlorobenzyl)-2-(1-methylazepan-4-yl)-1-phthalazinone Hydrochloride
4-(4-chlorobenzyl)-2-(1-methylazepan-4-yl)phthalazin-1(2H)-one hydrochloride
4-(p-Chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)-phthalazinone monohydrochloride
4-[ methyl]-2- phthalazin-1 -onehydrochloride
4-[(4-Chlorophenyl)methyl]-2-(1-methyl-4-azepanyl)phthalazin-1-one Hydrochloride
4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1-one hydrochloride
4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1-one;hydrochloride
4-[(4-CHLOROPHENYL)METHYL]-2-(HEXAHYDRO-1-METHYL-1H-AZEPIN-4-YL)PHTHALAZIN-1(2H)-ONE HYDROCHLORIDE
58581-89-8 (Parent)
79307-93-0
A 5610
A-5610
AB2000649
AC-5498
AC1L1GV0
ACM37932960
AKOS015895420
Allergodil
Allergodil;Rhinolast;Astelin;Optilas;Optivar
AN-10917
API0001572
AS-14079
Astelin
Astelin (TN)
Astepro
Azelastine (hydrochloride)
AZELASTINE HCl
AZELASTINE HYDROCHLORIDE
Azelastine hydrochloride (Astelin)
Azelastine hydrochloride (JP17/USAN)
Azelastine hydrochloride [USAN:JAN]
Azelastine Hydrochloride 1.0 mg/ml in Methanol (as free base)
Azelastine hydrochloride, >=98% (HPLC)
Azelastine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Azelastine Hydrochloride, pharmaceutical secondary standard; traceable to USP, PhEur
Azelastine hydrochloride, United States Pharmacopeia (USP) Reference Standard
Azelastine monohydrochloride
Azep
Azeptin
BCP0726000233
BCP9000369
BCPP000358
C22H24ClN3O.HCl
CAS-79307-93-0
CCG-100841
CCG-40046
CHEBI:2951
CHEMBL1200809
Corifina
CPD000469183
CS-2573
CTK4H9031
D00659
DSSTox_CID_25945
DSSTox_GSID_45945
DSSTox_RID_81243
DTXSID2045945
E-0659
EINECS 253-720-4
HE199844
HE199845
HMS1922F04
HY-B0462
I06-0528
J90045
LS-109215
MFCD00242783
MLS001401427
MLS006010756
MolPort-003-666-641
NC00091
NCGC00095173-01
NCGC00095173-02
NCGC00177979-05
NSC-758971
NSC758971
Optilas
Optilast
Pharmakon1600-01505340
PubChem20750
Radethazin
Rhinolast
S2552
SAM001246645
SCHEMBL36770
SMR000469183
SPECTRUM1505340
ST51052784
Tox21_111469
Tox21_111469_1
W- 979M
W-2979M
YEJAJYAHJQIWNU-UHFFFAOYSA-N
Zalastine

US Patents and Regulatory Information for OPTIVAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Speciality Lp OPTIVAR azelastine hydrochloride SOLUTION/DROPS;OPHTHALMIC 021127-001 May 22, 2000 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for OPTIVAR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mylan Speciality Lp OPTIVAR azelastine hydrochloride SOLUTION/DROPS;OPHTHALMIC 021127-001 May 22, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Mylan Speciality Lp OPTIVAR azelastine hydrochloride SOLUTION/DROPS;OPHTHALMIC 021127-001 May 22, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for OPTIVAR
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Ophthalmic Solution 0.05% ➤ Subscribe 2006-12-13

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Cerilliant
UBS
Fuji
Mallinckrodt
Teva
Harvard Business School
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.